5‐HT6 receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia

Abstract

Cognitive deficits in schizophrenia severely compromise quality of life and are poorly controlled by current antipsychotics. While 5-HT(6) receptor blockade holds special promise, molecular substrates underlying their control of cognition remain unclear. Using a proteomic strategy, we show that 5-HT(6) receptors physically interact with several proteins of the mammalian target of rapamycin (mTOR) pathway, including mTOR. Further, 5-HT(6) receptor activation increased mTOR signalling in rodent prefrontal cortex (PFC). Linking this signalling event to cognitive impairment, the mTOR inhibitor rapamycin prevented deficits in social cognition and novel object discrimination induced by 5-HT(6) agonists. In two developmental models of schizophrenia, specifically neonatal phencyclidine treatment and post-weaning isolation rearing, the activity of mTOR was enhanced in the PFC, and rapamycin, like 5-HT(6) antagonists, reversed these cognitive deficits. These observations suggest that recruitment of mTOR by prefrontal 5-HT(6) receptors contributes to the perturbed cognition in schizophrenia, offering new vistas for its therapeutic control.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 42

1. 1.

   Auerbach BD, Osterweil EK, Bear MF. Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature. 2011;480:63-68.

   Not in our library10.1038/nature10658

2. 2.

   Bockaert J, Fagni L, Dumuis A, Marin P. GPCR interacting proteins (GIP). Pharmacol Ther. 2004;103:203-221.

   Not in our library10.1016/j.pharmthera.2004.06.004

3. 3.

   Codony X, Vela JM, Ramirez MJ. 5-HT(6) receptor and cognition. Curr Opin Pharmacol. 2011;11:94-100.

   Not in our library10.1016/j.coph.2011.01.004

4. 4.

   Dan HC, Sun M, Yang L, Feldman RI, Sui XM, Ou CC, Nellist M, Yeung RS, Halley DJ, Nicosia SV, et al. Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem. 2002;277:35364-35370.

   Not in our library10.1074/jbc.m205838200

5. 5.

   Ehninger D, Han S, Shilyansky C, Zhou Y, Li W, Kwiatkowski DJ, Ramesh V, Silva AJ. Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis. Nat Med. 2008;14:843-848.

   Not in our library10.1038/nm1788

6. 6.

   Ehninger D, Silva AJ. Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders. Trends Mol Med. 2011;17:78-87.

   Not in our library10.1016/j.molmed.2010.10.002

7. 7.

   Fone KC, Porkess MV. Behavioural and neurochemical effects of post-weaning social isolation in rodents-relevance to developmental neuropsychiatric disorders. Neurosci Biobehav Rev. 2008;32:1087-1102.

   Not in our library10.1016/j.neubiorev.2008.03.003

8. 8.

   Garami A, Zwartkruis FJ, Nobukuni T, Joaquin M, Roccio M, Stocker H, Kozma SC, Hafen E, Bos JL, Thomas G. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell. 2003;11:1457-1466.

   Not in our library10.1016/s1097-2765(03)00220-x

9. 9.

   Gray JA, Roth BL. The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007;12:904-922.

   Not in our library10.1038/sj.mp.4002062

10. 10.

    Hashimoto T, Volk DW, Eggan SM, Mirnics K, Pierri JN, Sun Z, Sampson AR, Lewis DA. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci. 2003;23:6315-6326.

    Not in our library10.1523/jneurosci.23-15-06315.2003

11. 11.

    Hirst WD, Stean TO, Rogers DC, Sunter D, Pugh P, Moss SF, Bromidge SM, Riley G, Smith DR, Bartlett S, et al. SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur J Pharmacol. 2006;553:109-119.

    Not in our library10.1016/j.ejphar.2006.09.049

12. 12.

    Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 2003;17:1829-1834.

    Not in our library10.1101/gad.1110003

13. 13.

    Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol. 2002;4:648-657.

    Not in our library10.1038/ncb839

14. 14.

    Insel TR. Rethinking schizophrenia. Nature. 2010;468:187-193.

    Not in our library10.1038/nature09552

15. 15.

    Johnson CN, Ahmed M, Miller ND. 5-HT6 receptor antagonists: prospects for the treatment of cognitive disorders including dementia. Curr Opin Drug Discov Dev. 2008;11:642-654.

    Not in our library

16. 16.

    Jones CA, Watson DJ, Fone KC. Animal models of schizophrenia. Br J Pharmacol. 2011;164:1162-1194.

    Not in our library10.1111/j.1476-5381.2011.01386.x

17. 17.

    Kaizuka T, Hara T, Oshiro N, Kikkawa U, Yonezawa K, Takehana K, Iemura S, Natsume T, Mizushima N. Tti1 and Tel2 are critical factors in mammalian target of rapamycin complex assembly. J Biol Chem. 2010;285:20109-20116.

    Not in our library10.1074/jbc.m110.121699

18. 18.

    Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274-293.

    Not in our library10.1016/j.cell.2012.03.017

19. 19.

    Lewis DA, Gonzalez-Burgos G. Neuroplasticity of neocortical circuits in schizophrenia. Neuropsychopharmacology. 2008;33:141-165.

    Not in our library10.1038/sj.npp.1301563

20. 20.

    Loiseau F, Dekeyne A, Millan MJ. Pro-cognitive effects of 5-HT6 receptor antagonists in the social recognition procedure in rats: implication of the frontal cortex. Psychopharmacology (Berl). 2008;196:93-104.

    Not in our library10.1007/s00213-007-0934-5

21. 21.

    Maere S, Heymans K, Kuiper M. BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics. 2005;21:3448-3449.

    Not in our library10.1093/bioinformatics/bti551

22. 22.

    Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell. 2002;10:151-162.

    Not in our library10.1016/s1097-2765(02)00568-3

23. 23.

    Marcos B, Chuang TT, Gil-Bea FJ, Ramirez MJ. Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat. Br J Pharmacol. 2008;155:434-440.

    Not in our library10.1038/bjp.2008.281

24. 24.

    Marsden CA, King MV, Fone KC. Influence of social isolation in the rat on serotonergic function and memory-relevance to models of schizophrenia and the role of 5-HT receptors. Neuropharmacology. 2011;61:400-407.

    Not in our library10.1016/j.neuropharm.2011.03.003

25. 25.

    Millan MJ, Agid Y, Brune M, Bullmore ET, Carter CS, Clayton NS, Connor R, Davis S, Deakin B, Derubeis RJ, et al. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov. 2012;11:141-168.

    Not in our library10.1038/nrd3628

26. 26.

    Millan MJ, Marin P, Bockaert J, Mannoury la Cour C. Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions. Trends Pharmacol Sci. 2008;29:454-464.

    Not in our library10.1016/j.tips.2008.06.007

27. 27.

    Mitchell ES, Neumaier JF. 5-HT6 receptors: a novel target for cognitive enhancement. Pharmacol Ther. 2005;108:320-333.

    Not in our library10.1016/j.pharmthera.2005.05.001

28. 28.

    Poullet P, Carpentier S, Barillot E. myProMS, a web server for management and validation of mass spectrometry-based proteomic data. Proteomics. 2007;7:2553-2556.

    Not in our library10.1002/pmic.200600784

29. 29.

    Rogers DC, Hagan JJ. 5-HT6 receptor antagonists enhance retention of a water maze task in the rat. Psychopharmacology (Berl). 2001;158:114-119.

    Not in our library10.1007/s002130100840

30. 30.

    Santini E, Heiman M, Greengard P, Valjent E, Fisone G. Inhibition of mTOR signaling in Parkinson's disease prevents l-DOPA-induced dyskinesia. Sci Signal. 2009;2:ra36.

    Not in our library10.1126/scisignal.2000308

31. 31.

    Schechter LE, Lin Q, Smith DL, Zhang G, Shan Q, Platt B, Brandt MR, Dawson LA, Cole D, Bernotas R, et al. Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466. Neuropsychopharmacology. 2008;33:1323-1335.

    Not in our library10.1038/sj.npp.1301503

32. 32.

    Snyder GL, Girault JA, Chen JY, Czernik AJ, Kebabian JW, Nathanson JA, Greengard P. Phosphorylation of DARPP-32 and protein phosphatase inhibitor-1 in rat choroid plexus: regulation by factors other than dopamine. J Neurosci. 1992;12:3071-3083.

    Not in our library10.1523/jneurosci.12-08-03071.1992

33. 33.

    Subramaniam S, Napolitano F, Mealer RG, Kim S, Errico F, Barrow R, Shahani N, Tyagi R, Snyder SH, Usiello A. Rhes, a striatal-enriched small G protein, mediates mTOR signaling and l-DOPA-induced dyskinesia. Nat Neurosci. 2011;15:191-193.

    Not in our library10.1038/nn.2994

34. 34.

    Subramaniam S, Snyder SH. Huntington's disease is a disorder of the corpus striatum: focus on Rhes (Ras homologue enriched in the striatum). Neuropharmacology. 2011;60:1187-1192.

    Not in our library10.1016/j.neuropharm.2010.10.025

35. 35.

    Swiech L, Perycz M, Malik A, Jaworski J. Role of mTOR in physiology and pathology of the nervous system. Biochim Biophys Acta. 2008;1784:116-132.

    Not in our library10.1016/j.bbapap.2007.08.015

36. 36.

    Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol. 2003;13:1259-1268.

    Not in our library10.1016/s0960-9822(03)00506-2

37. 37.

    Wang X, Proud CG. mTORC1 signaling: what we still don't know. J Mol Cell Biol. 2011;3:206-220.

    Not in our library10.1093/jmcb/mjq038

38. 38.

    Watson DJ, Marsden CA, Millan MJ, Fone KC. Blockade of dopamine D3 but not D2 receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: implications for schizophrenia and its treatment. Int J Neuropsychopharmacol. 2011;18:1-14.

    Not in our library10.1017/s1461145711000435

39. 39.

    Woolley ML, Bentley JC, Sleight AJ, Marsden CA, Fone KC. A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology. 2001;41:210-219.

    Not in our library10.1016/s0028-3908(01)00056-9

40. 40.

    Woolley ML, Marsden CA, Fone KC. 5-ht6 receptors. Curr Drug Targets CNS Neurol Disord. 2004;3:59-79.

    Not in our library10.2174/1568007043482561

Cited by papers we hold 4

• Tryptophan Metabolism Acts as a New Anti‐Ferroptotic Pathway to Mediate Tumor Growth · 2023
  No notice
• Dual Role of Autophagy in Diseases of the Central Nervous System · 2019
  No notice
• Reelin and Neuropsychiatric Disorders · 2016
  No notice
• Ribosomal Protein S6 Phosphorylation in the Nervous System: From Regulation to Function · 2015
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.